None
Conditions
Interventions
Group A (Remazolam combined with cyclopofol):Remimazolam 5mg intravenously cyclopofol 0.4mg/kg.
Group B(Afentanil combined with cyclopofol):Intravenous alfentanil 10ug/kg cyclopofol 0.4mg/kg.
Sponsors
The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-60 years; 2. American Society of Anesthesiologists (ASA) grade I or II; 3. Body mass index (BMI) 18-28 kg/m^2; 4. Signed informed consent form for the study by the person or family members.
Exclusion criteria
Exclusion criteria: 1. Allergic to the anesthetic ingredients used in the study; 2.Complicated with serious heart, lung, liver and kidney Other organs are not fully functional; 3.combined with mental system diseases; 4.Taking sedatives or analgesics for a long time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Check for respiratory depression throughout the process (pulse oxygen saturation (SpO2) < 90%);The number of times the patient experienced somatokinetic reactions during the examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug-related conditions (number and dosage of cyclopofol or propofol throughout the operation);Postoperative pain Score (VAS score);Blood pressure;Heart rate;MOAA/S score; | — |
Countries
China
Contacts
Public ContactJing Li
The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed